BioSpace News Archive

Revamp Medical, a medical device company developing a percutaneous device for the treatment of acute heart failure (AHF), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the Doraya™ device. The Doraya is a temporary catheter, placed in the Inferior Vena Cava below the r

Path to Better Health Study also reveals desire for digital health care solutions to support chronic care, mental health needs.

Investment co-led by Volition Capital and Greycroft to propel Medly’s leadership in the $500B+ digital on-demand pharmacy market

Natera, Inc. (NASDAQ: NTRA), a pioneer and global leader in cell-free DNA testing, has received the Force for Change Illuminator award from LWE, accepted by Sheetal Parmar , Natera’s VP of Medical Affairs.

Syntellis Performance Solutions, a leading provider of enterprise performance management (EPM) software, data, and analytics solutions, has been ranked by Black Book Research as the top overall Healthcare Analytics Solutions vendor in the recent Benchmarking & Comparative Analytics Software rankings.

Asks agency to update requirements to reflect advances in technology to improve security, workflow, and adoption

- 7,200+ survey responses reveal effects of coronavirus infection and shelter-in-place guidelines on the Parkinson’s community - Tremendous response over 30 days reflects capability of technology-enabled research and community’s commitment to rapidly shape scientific avenues - Data is available now to qualified researchers worldwide through the Fox Data Exploration Network (foxden.michaeljfox.org)

Moderna, Inc. (Nasdaq: MRNA), a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines, announced that it will become a component of the NASDAQ-100 Index ® (Nasdaq: NDX), the NASDAQ-100 Equal Weighted Index (Nasdaq: NDXE) and the NASDAQ-100 Ex-Tech Sector Index (Nasdaq: NDXX) prior to market open on Monday, July 20, 2020.

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX), a leader in personalized cannabinoid medicine focused on cancer and its side effects, announced today that it has initiated activities to penetrate European markets in order to offer a test based on its diagnostic platform to patients who suffer from cancer and a

Alliance Physical Therapy Partners announced that Richard Leaver will transition to become the company’s Chief Executive Officer, effective July 20th.